Image
Figure Caption

Fig. 4 cyp26a1 protects the hindbrain from exogenous RA. Wild-type (left column) and cyp26a1-/- (right column) embryos treated with DMSO (A,B), 10 μM DEAB (C,D) or 10 μM DEAB + 5 nM RA (E-L). RNA in situ hybridizations use the markers described in Fig. 2, except for I,J, which is a mix of en3 (bracket), krox20 (r3, r5), dlx2 [cranial neural crest (cnc) and forebrain (fb)] and myoD (somites; s). Large bracket in A indicates the r7-r8 region, which is elongated in cyp26a1 mutants (B). (C) In DEAB-treated embryos, posterior rhombomeres (r5-r8) are absent (arrow indicates the absence of high hoxd4 expression characteristic of r7-r8). (D) This phenotype is partially rescued in cyp26a1 mutants, as seen by rescue of r5 but not of r7-r8. (E-L) The DEAB phenotype is fully rescued in wild-type embryos by treatment with 5 nM RA (E,G,I,K) whereas, in cyp26a1 mutants, this low dose of RA causes strong posteriorization of the brain (F,H,J,L). This phenotype resembles that of wild-type embryos treated with 200 nM RA (inset in J). Scale bar: 100 μm. os: optic stalk; e: eye; p: pronephros.

Figure Data
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Development